We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis to License Idenix Hepatitis C Compound
Novartis to License Idenix Hepatitis C Compound
March 31, 2006
Novartis will pay up to $525 million for the rights to Idenix Pharmaceuticals’ experimental Hepatitis C treatment valopicitabine, the firms announced March 29.